Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Additional Information (Details)

v3.20.1
Summary of Significant Accounting Policies - Additional Information (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Aug. 31, 2018
USD ($)
Program
Mar. 31, 2020
USD ($)
$ / shares
Mar. 31, 2019
USD ($)
$ / shares
Net loss   $ (19,595) $ (14,250)
Net loss per share | $ / shares   $ (0.84) $ (0.62)
2018 Merck Agreement      
Upfront payment received $ 60,000    
Number of research programs | Program 2    
Transaction price   $ 60,000  
Revenue recognized performance obligation   $ 47,100  
Number of target programs estimated service period   3 years  
Decrease in revenue due to adjustments   $ 5,100  
Net loss   $ 5,100  
Net loss per share | $ / shares   $ 0.22